Use of Cyclosporine in Uterine Transplantation | Zendy

Srdjan Saso | Zendy; Karl Logan | Zendy; Y. Abdallah | Zendy; Louay Louis | Zendy; Sadaf GhaemMaghami | Zendy; Jr. Smith | Zendy; Giuseppe Del Priore | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of Cyclosporine in Uterine Transplantation

Author(s) -

Srdjan Saso,

Karl Logan,

Y. Abdallah,

Louay Louis,

Sadaf GhaemMaghami,

Jr. Smith,

Giuseppe Del Priore

Publication year - 2011

Publication title -

journal of transplantation

Language(s) - English

Resource type - Journals

eISSN - 2090-0015

pISSN - 2090-0007

DOI - 10.1155/2012/134936

Subject(s) - medicine , fetus , infertility , transplantation , offspring , pregnancy , gynecology , intensive care medicine , obstetrics , surgery , genetics , biology

Uterine transplantation has been proposed as a possible solution to absolute uterine factor infertility untreatable by any other option. Since the first human attempt in 2000, various teams have tried to clarify which immunosuppressant would be most suitable for protecting the allogeneic uterine graft while posing a minimal risk to the fetus. Cyclosporine A (CsA) is an immunosuppressant widely used by transplant recipients. It is currently being tested as a potential immunosuppressant to be used during UTn. Its effect on the mother and fetus and its influence upon the graft during pregnancy have been of major concern. We review the role of CsA in UTn and its effect on pregnant transplant recipients and their offspring.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research